Core Insights - Immunovant, Inc. reported a first-quarter fiscal 2026 adjusted net loss of $0.60 per share, which is narrower than the Zacks Consensus Estimate of a loss of $0.69 and matches the loss from the same quarter last year [1][4] Financial Performance - Research and development expenses reached $101.2 million, reflecting a 34% increase from the previous year, driven by clinical study activities for IMVT-1402 and higher personnel costs, partially offset by reduced costs in batoclimab studies [2] - General and administrative expenses were $26 million, up 38% year over year, primarily due to increased personnel-related expenses [3] - As of June 30, 2025, the company had a cash balance of $598.9 million, down from $714 million as of March 31, 2025, with expectations to fund clinical activities through 2027 [3] Pipeline Developments - IMVT-1402 is the lead drug candidate, being studied for six indications, with key data readouts expected through 2027 [4][6] - The company plans to initiate clinical studies for IMVT-1402 in a total of 10 indications by March 31, 2026, leveraging existing data from batoclimab studies for financial efficiencies [5] - During the first quarter of fiscal 2026, Immunovant initiated a second potentially registrational study of IMVT-1402 for Graves' disease and a study for Sjögren's disease [7] Upcoming Milestones - In 2026, the company plans to share open-label data from its difficult-to-treat rheumatoid arthritis study and top-line results from the cutaneous lupus erythematosus proof-of-concept study [7] - Top-line results from potentially registrational studies in difficult-to-treat rheumatoid arthritis, Graves' disease, and myasthenia gravis are expected in 2027 [7] Additional Candidates - Immunovant is also evaluating batoclimab in mid-late-stage studies for Graves' disease and thyroid eye disease, with new proof-of-concept data expected to be reported in September 2025 [8][10]

Financial Data and Key Metrics Changes - The company reported an adjusted net loss of $170 million for the quarter, with cash utilization of approximately $200 million outside of the share repurchase program [25][26] - The balance sheet remains strong with $4.5 billion in cash and no debt, alongside a significantly reduced share count due to the share repurchase program [25][26] Business Line Data and Key Metrics Changes - The company is focused on the development of IVT-1402 and Immunovant, aiming to establish a best-in-class anti-FcRn antibody [6] - The registrational data for brepcitinib in dermatomyositis is expected in the second half of the year, which is crucial for the commercial launch of the drug [6][19] - The company has multiple ongoing registrational trials, with five trials for IVT-1402 currently in progress [9] Market Data and Key Metrics Changes - The company is preparing for a pivotal trial in Graves' disease, with expectations for significant data to be released soon [19][27] - The competitive landscape includes multiple programs from other companies, but the company believes its oral therapy will provide a unique advantage [19][96] Company Strategy and Development Direction - The company aims to expand its commercial footprint significantly over the next few years, starting with pivotal data in dermatomyositis and subsequent launches across its FcRn portfolio [10][19] - The company is actively engaging in business development, looking for transformational late-stage opportunities, particularly in the current choppy market [48][54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data and its potential impact on the company's commercial strategy, particularly in Graves' disease [27][76] - The company is focused on ensuring successful clinical execution and is confident in its ability to meet timelines for upcoming trials [71][72] Other Important Information - The company completed a $1 billion share repurchase program, reducing its share count by over 15% [10] - An additional $500 million repurchase program has been authorized for opportunistic use as market conditions fluctuate [10] Q&A Session Summary Question: Data availability at the time of top line results for brepcitinib - Management expects to have top line and key secondary data available contemporaneously with the results, with a potential filing for approval at the beginning of next year [29][31] Question: Trial design for the Graves' disease study - The rationale for testing a lower dose in the second Graves' trial is to ensure FDA approval and advocate for a minimally efficacious dose [32][33] Question: Definition of a flare in the trial - Management indicated that the definition of a flare and treatment protocols are designed to ensure accurate identification of patients who are worsening [35][38] Question: Context around upcoming Graves' remission data - Any amount of meaningful remission would be considered practice-changing for doctors treating Graves' disease patients [44][45] Question: Business development outlook - The company remains opportunistic in its business development strategy, particularly in the current market environment [48][54] Question: Enrollment status for ongoing studies - Enrollment for IVT-1402 trials is on track, with the team actively engaged and enthusiastic about the indications [70][71] Question: Importance of upcoming data at ATA - The data is expected to highlight the transformative potential of the drug for Graves' patients, which could significantly impact enrollment and physician enthusiasm [75][76] Question: Roadmap for pivotal development and potential filing year for NIU - The company is on track to generate data for NIU in 2027, with plans for a supplemental NDA filing shortly thereafter [83][84]

PART I. FINANCIAL INFORMATION This section provides a comprehensive overview of the company's financial performance and position [Item 1. Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28unaudited%29) This section presents the unaudited condensed consolidated financial statements of Immunovant, Inc. for the quarter ended June 30, 2025, including balance sheets, statements of operations, comprehensive loss, stockholders' equity, and cash flows, along with detailed notes explaining the company's business, accounting policies, material agreements, and financial position [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets%20as%20of%20June%2030%2C%202025%20and%20March%2031%2C%202025) This section provides a snapshot of the company's financial position, detailing assets, liabilities, and stockholders' equity at specific dates Condensed Consolidated Balance Sheets (in thousands) | Item | June 30, 2025 | March 31, 2025 | | :---------------------------------- | :-------------- | :--------------- | | **Assets:** | | | | Cash and cash equivalents | $598,912 | $713,971 | | Total current assets | $651,763 | $767,760 | | Total assets | $661,440 | $776,222 | | **Liabilities and Stockholders' Equity:** | | | | Total current liabilities | $52,900 | $68,775 | | Total liabilities | $52,900 | $68,775 | | Total stockholders' equity | $608,540 | $707,447 | | Total liabilities and stockholders' equity | $661,440 | $776,222 | - Cash and cash equivalents decreased by **$115.059 million** from March 31, 2025, to June 30, 2025[12](index=12&type=chunk)[23](index=23&type=chunk) - Total stockholders' equity decreased by **$98.907 million** from March 31, 2025, to June 30, 2025[12](index=12&type=chunk) [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section presents the company's revenues, expenses, and net loss over specific reporting periods Condensed Consolidated Statements of Operations (in thousands, except per share data) | Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :------------------------------------------ | :------------------------------- | :------------------------------- | | Research and development expenses | $101,200 | $75,473 | | General and administrative expenses | $26,024 | $18,808 | | Total operating expenses | $127,224 | $94,281 | | Interest income, net | $(6,337) | $(7,180) | | Other income, net | $(1,187) | $(28) | | Loss before provision for income taxes | $(119,700) | $(87,073) | | Provision for income taxes | $913 | $77 | | Net loss | $(120,613) | $(87,150) | | Net loss per common share – basic and diluted | $(0.71) | $(0.60) | | Weighted-average common shares outstanding | 170,872,994 | 146,085,729 | - Net loss increased by **$33.463 million** (**38.4%**) from **$87.150 million** in Q2 2024 to **$120.613 million** in Q2 2025[15](index=15&type=chunk) - Research and development expenses increased by **$25.727 million** (**34.1%**) year-over-year[15](index=15&type=chunk) [Condensed Consolidated Statements of Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section details the company's net loss and other comprehensive income or loss components Condensed Consolidated Statements of Comprehensive Loss (in thousands) | Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | | Net loss | $(120,613) | $(87,150) | | Foreign currency translation adjustments | $278 | $(88) | | Total other comprehensive income (loss) | $278 | $(88) | | Comprehensive loss | $(120,335) | $(87,238) | - Comprehensive loss increased by **$33.097 million** (**37.9%**) from **$87.238 million** in Q2 2024 to **$120.335 million** in Q2 2025[18](index=18&type=chunk) - Foreign currency translation adjustments resulted in income of **$278 thousand** in Q2 2025, compared to a loss of **$88 thousand** in Q2 2024[18](index=18&type=chunk) [Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section outlines changes in the company's equity accounts, including common stock, additional paid-in capital, and accumulated deficit Condensed Consolidated Statements of Stockholders' Equity (in thousands, except share data) | Item | Balance at March 31, 2025 | Stock options exercised and RSUs vested | Capital contribution – stock-based compensation | Stock-based compensation | Foreign currency translation adjustments | Net loss | Balance at June 30, 2025 | | :------------------------------------------ | :------------------------ | :-------------------------------------- | :-------------------------------------------- | :----------------------- | :--------------------------------------- | :--------- | :----------------------- | | Common stock (shares) | 170,111,593 | 957,583 | — | — | — | — | 171,069,176 | | Common stock (amount) | $16 | $0 | $0 | $0 | $0 | $0 | $16 | | Additional paid-in capital | $1,945,495 | $2,918 | $115 | $18,395 | $0 | $0 | $1,966,923 | | Accumulated other comprehensive income | $1,459 | $0 | $0 | $0 | $278 | $0 | $1,737 | | Accumulated deficit | $(1,239,523) | $0 | $0 | $0 | $0 | $(120,613) | $(1,360,136) | | **Total stockholders' equity** | **$707,447** | **$2,918** | **$115** | **$18,395** | **$278** | **$(120,613)** | **$608,540** | - Total stockholders' equity decreased by **$98.907 million** from **$707.447 million** at March 31, 2025, to **$608.540 million** at June 30, 2025, primarily due to the net loss[20](index=20&type=chunk) - Stock-based compensation contributed **$18.395 million** to additional paid-in capital during the three months ended June 30, 2025[20](index=20&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section summarizes the cash inflows and outflows from operating, investing, and financing activities Condensed Consolidated Statements of Cash Flows (in thousands) | Activity | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | | Net cash used in operating activities | $(117,411) | $(76,199) | | Net cash used in investing activities | $0 | $(182) | | Net cash provided by financing activities | $2,918 | $686 | | Effect of exchange rate changes on cash and cash equivalents | $(566) | $335 | | Net change in cash and cash equivalents | $(115,059) | $(75,360) | | Cash and cash equivalents – beginning of period | $713,971 | $635,365 | | Cash and cash equivalents – end of period | $598,912 | $560,005 | - Net cash used in operating activities increased by **$41.212 million** (**54.1%**) to **$117.411 million** in Q2 2025, compared to **$76.199 million** in Q2 2024[23](index=23&type=chunk) - Net cash provided by financing activities increased by **$2.232 million** (**325.4%**) to **$2.918 million** in Q2 2025, primarily from stock options exercised[23](index=23&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the condensed consolidated financial statements [Note 1 — Description of Business and Liquidity](index=9&type=section&id=Note%201%20%E2%80%94%20Description%20of%20Business%20and%20Liquidity) This note describes the company's business, product candidates, and current liquidity position - Immunovant is a clinical-stage immunology company developing IMVT-1402 and batoclimab, novel FcRn-targeting monoclonal antibodies for autoimmune diseases[26](index=26&type=chunk) Liquidity and Financial Position (as of June 30, 2025) | Metric | Amount (in thousands) | | :------------------------- | :-------------------- | | Cash and cash equivalents | $598,912 | | Accumulated deficit | $(1,360,136) | - The company has not generated any revenue to date and expects to incur additional losses, requiring future capital raises through equity, debt, or collaborations[28](index=28&type=chunk)[29](index=29&type=chunk) [Note 2 — Summary of Significant Accounting Policies](index=9&type=section&id=Note%202%20%E2%80%94%20Summary%20of%20Significant%20Accounting%20Policies) This note outlines the key accounting principles and methods applied in the financial statements - Financial statements are unaudited, prepared in accordance with U.S. GAAP for interim reporting, and include all normal and recurring adjustments. The fiscal year ends March 31[30](index=30&type=chunk)[31](index=31&type=chunk) - Key estimates and assumptions are made for assets, liabilities, stock-based compensation, litigation, clinical trial accruals, R&D costs, and income taxes, with actual results potentially differing[32](index=32&type=chunk) - Research and development costs are expensed as incurred, including employee-related costs and third-party expenses for clinical trial activities and manufacturing. Cost-sharing arrangements reduce R&D expenses[37](index=37&type=chunk)[38](index=38&type=chunk) Potentially Dilutive Securities Excluded from EPS Calculation (as of June 30) | Security Type | 2025 | 2024 | | :-------------------------- | :----------- | :----------- | | Preferred stock as converted | 10,000 | 10,000 | | Stock options | 14,776,873 | 14,031,041 | | Restricted stock units | 4,723,316 | 4,016,235 | | **Total** | **19,510,189** | **18,057,276** | [Note 3 — Material Agreements](index=12&type=section&id=Note%203%20%E2%80%94%20Material%20Agreements) This note details the company's significant contractual agreements, including licensing and manufacturing - Immunovant holds exclusive, royalty-bearing rights to develop, import, use, and commercialize batoclimab and IMVT-1402 in the Licensed Territory through an assignment of the HanAll Agreement[47](index=47&type=chunk)[49](index=49&type=chunk) HanAll Agreement Financials (as of June 30, 2025) | Item | Amount | | :------------------------------------------------ | :------------- | | Upfront payment | $30.0 million | | Shared R&D costs (expired) | Up to $20.0 million | | Milestone payments (aggregate paid) | $32.5 million | | Milestone payments (aggregate remaining potential) | Up to $420.0 million | | Royalties | Mid-single digits to mid-teens % of net sales | Samsung Biologics Product Service Agreement Minimum Purchase Commitment (as of June 30, 2025) | Fiscal Year Ending March 31 | Amount (in millions) | | :---------------------------- | :------------------- | | Remainder of FY2026 | $5.0 | | FY2028 | $10.1 | | FY2029 | $14.0 | | FY2030 | $14.0 | | **Total Remaining Commitment** | **$43.1** | [Note 4 — Accrued Expenses and Other Current Liabilities](index=13&type=section&id=Note%204%20%E2%80%94%20Accrued%20Expenses%20and%20Other%20Current%20Liabilities) This note provides a breakdown of the company's accrued expenses and other short-term liabilities Accrued Expenses and Other Current Liabilities (in thousands) | Item | June 30, 2025 | March 31, 2025 | | :---------------------------------- | :-------------- | :--------------- | | Research and development expenses | $35,444 | $32,622 | | Accrued bonuses | $4,909 | $15,618 | | Legal and other professional fees | $794 | $789 | | Employee severance | $1,072 | $263 | | Due to Roivant Sciences Ltd. | $862 | $273 | | Other expenses | $1,976 | $1,554 | | **Total current liabilities** | **$45,057** | **$51,119** | - Total accrued expenses and other current liabilities decreased by **$6.062 million** (**11.86%**) from March 31, 2025, to June 30, 2025, primarily driven by a **$10.709 million** decrease in accrued bonuses[52](index=52&type=chunk) [Note 5 — Related Party Transactions](index=13&type=section&id=Note%205%20%E2%80%94%20Related%20Party%20Transactions) This note discloses transactions and agreements with related parties, including affiliates - Expenses incurred under Services Agreements with RSI and RSG increased from **$0.1 million** for the three months ended June 30, 2024, to **$0.8 million** for the same period in 2025[54](index=54&type=chunk) - The Cooperation Agreement with RSL outlines information sharing and reporting obligations, and indemnification, but no financial transactions have occurred under this agreement[55](index=55&type=chunk) [Note 6 — Income Taxes](index=14&type=section&id=Note%206%20%E2%80%94%20Income%20Taxes) This note explains the company's income tax provision, effective tax rate, and deferred tax assets/liabilities Effective Tax Rates (Three Months Ended June 30) | Period | Effective Tax Rate | | :---------------------- | :----------------- | | June 30, 2025 | (0.76)% | | June 30, 2024 | (0.09)% | - The effective tax rate is primarily driven by jurisdictional earnings and a valuation allowance that eliminates global net deferred tax assets[57](index=57&type=chunk)[58](index=58&type=chunk) - The company is evaluating the impact of the One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, which includes broad tax reform provisions[59](index=59&type=chunk) [Note 7 — Stockholders' Equity](index=14&type=section&id=Note%207%20%E2%80%94%20Stockholders%27%20Equity) This note details the components of stockholders' equity, including common stock and preferred stock - **10,000 shares** of Series A preferred stock are outstanding, held by RSL, and will automatically convert to common stock if RSL holds less than **25%** of total voting power[60](index=60&type=chunk)[61](index=61&type=chunk) Common Stock Shares Issued and Outstanding | Date | Shares Issued and Outstanding | | :---------------- | :---------------------------- | | June 30, 2025 | 171,069,176 | | March 31, 2025 | 170,111,593 | Shares of Common Stock Reserved for Issuance | Item | June 30, 2025 | March 31, 2025 | | :-------------------------------- | :-------------- | :--------------- | | Conversion of Series A preferred stock | 10,000 | 10,000 | | Stock options outstanding | 14,783,964 | 12,963,834 | | Restricted stock units outstanding | 5,507,546 | 4,043,674 | | Equity awards available for future grants | 8,589,913 | 6,027,035 | | **Total** | **28,891,423** | **23,044,543** | [Note 8 — Stock-Based Compensation](index=15&type=section&id=Note%208%20%E2%80%94%20Stock-Based%20Compensation) This note describes the company's equity incentive plans and the expense recognized for stock-based awards - The 2019 Equity Incentive Plan automatically increased by **6,804,463 shares** on April 1, 2025, and as of June 30, 2025, **8,589,913 shares** remained available for future grants[65](index=65&type=chunk) Stock Option Activity Summary (Three Months Ended June 30, 2025) | Item | Number of Stock Options | Weighted Average Exercise Price | | :-------------------------- | :---------------------- | :------------------------------ | | Balance - March 31, 2025 | 12,963,834 | $12.00 | | Granted | 2,838,551 | $15.28 | | Exercised | (433,635) | $6.97 | | Forfeited | (584,983) | $16.40 | | Expired | (6,894) | $24.88 | | **Balance - June 30, 2025** | **14,776,873** | **$12.62** | Stock-based Compensation Expense (in thousands) | Expense Category | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | | Research and development expenses | $7,865 | $7,185 | | General and administrative expenses | $10,530 | $6,258 | | **Total stock-based compensation** | **$18,395** | **$13,443** | - Total unrecognized compensation expense for nonvested stock options and RSUs was **$61.3 million** and **$79.6 million**, respectively, as of June 30, 2025, to be recognized over approximately **2.79** to **2.92** years[70](index=70&type=chunk) [Note 9 — Segment Information](index=17&type=section&id=Note%209%20%E2%80%94%20Segment%20Information) This note provides information about the company's operating segments and how performance is managed - Immunovant operates in a single operating segment encompassing all activities related to the research, development, and manufacturing of its product candidates[43](index=43&type=chunk)[72](index=72&type=chunk) Significant Segment Expenses (in thousands) for Three Months Ended June 30 | Expense Category | 2025 | 2024 | | :------------------------------------------ | :------- | :------- | | Endocrine diseases R&D | $19,329 | $15,913 | | Neurological diseases R&D | $20,937 | $18,479 | | Rheumatology diseases R&D | $8,209 | $0 | | Dermatology diseases R&D | $5,145 | $0 | | Other clinical and nonclinical R&D | $2,392 | $6,401 | | Other unallocated R&D | $10,685 | $10,160 | | Personnel-related R&D | $34,503 | $24,520 | | Personnel-related G&A | $17,832 | $10,696 | | Other G&A | $8,192 | $8,112 | | Interest income, net | $(6,337) | $(7,180) | | Other segment items | $(274) | $49 | | **Net loss** | **$120,613** | **$87,150** | [Note 10 — Commitments and Contingencies](index=18&type=section&id=Note%2010%20%E2%80%94%20Commitments%20and%20Contingencies) This note discloses the company's material commitments and potential contingent liabilities - As of June 30, 2025, the company was not party to any material legal proceedings and had no recorded contingent liabilities[75](index=75&type=chunk) Samsung Biologics Minimum Purchase Obligation (as of June 30, 2025) | Fiscal Year Ending March 31 | Amount (in millions) | | :---------------------------- | :------------------- | | Remainder of FY2026 | $5.0 | | FY2028 | $10.1 | | FY2029 | $14.0 | | FY2030 | $14.0 | | **Total Remaining Obligation** | **$43.1** | - Macroeconomic and geopolitical factors, including inflation, interest rates, trade policies, and conflicts, could impact the company's future operational and financial performance, especially clinical trial plans and timelines[78](index=78&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section analyzes the company's financial condition, results of operations, and liquidity, highlighting key business developments [Overview](index=19&type=section&id=Overview) This section introduces the company's business, strategic focus, and key product candidates - Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor, for autoimmune diseases driven by pathogenic IgG antibodies[82](index=82&type=chunk) - IMVT-1402 demonstrated deep, dose-dependent IgG reductions in Phase 1, with **600 mg** weekly dosing expected to achieve approximately **80%** IgG reduction, offering potentially best-in-class efficacy[84](index=84&type=chunk)[85](index=85&type=chunk) - IMVT-1402 showed no or minimal reductions in albumin and no or minimal increases in LDL cholesterol, which are off-target effects observed with some other anti-FcRn antibodies[85](index=85&type=chunk) - The company has initiated studies in six indications for IMVT-1402, including potentially registrational trials in GD, D2T RA, MG, CIDP, SjD, and a proof-of-concept trial in CLE, all using the YpsoMate® autoinjector[86](index=86&type=chunk) [Recent Developments in Our Clinical Programs](index=20&type=section&id=Recent%20Developments%20in%20Our%20Clinical%20Programs) This section highlights recent progress and milestones in the company's clinical development pipeline [Endocrine Diseases](index=20&type=section&id=Endocrine%20Diseases) This section provides updates on clinical programs targeting endocrine diseases - Two potentially registrational trials for IMVT-1402 in adults with Graves' Disease (GD) were initiated in December 2024 and June 2025, with top-line results expected in **2027**[88](index=88&type=chunk) - A Phase 2 proof-of-concept trial of batoclimab for uncontrolled GD is ongoing, with additional data, including remission data, expected at the American Thyroid Association (ATA) Annual Meeting in September 2025[89](index=89&type=chunk) - Top-line results from the Phase 3 clinical program evaluating batoclimab for active moderate-to-severe Thyroid Eye Disease (TED) are planned for the second half of calendar year 2025[90](index=90&type=chunk) [Neurological Diseases](index=20&type=section&id=Neurological%20Diseases) This section provides updates on clinical programs targeting neurological diseases - A potentially registrational trial for IMVT-1402 in adults with Myasthenia Gravis (MG) was initiated in March 2025, with top-line results expected in **2027**[92](index=92&type=chunk) - A potentially registrational trial for IMVT-1402 in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) was initiated in March 2025, with top-line results expected in **2028**[93](index=93&type=chunk) - The company is leveraging data and learnings from prior batoclimab MG and CIDP studies to inform and accelerate IMVT-1402 programs[91](index=91&type=chunk) [Rheumatology Diseases](index=21&type=section&id=Rheumatology%20Diseases) This section provides updates on clinical programs targeting rheumatology diseases - A potentially registrational trial for IMVT-1402 in ACPA-positive difficult-to-treat rheumatoid arthritis (D2T RA) was initiated in December 2024, with initial results from the open-label portion expected in **2026**[94](index=94&type=chunk) - A potentially registrational trial for IMVT-1402 in Sjögren's disease (SjD) was initiated in June 2025, with top-line results expected in **2028**[95](index=95&type=chunk) [Dermatology Diseases](index=21&type=section&id=Dermatology%20Diseases) This section provides updates on clinical programs targeting dermatology diseases - A proof-of-concept trial evaluating IMVT-1402 in cutaneous lupus erythematosus (CLE) was initiated in February 2025, with top-line results expected in **2026**[96](index=96&type=chunk) [Macroeconomic Considerations](index=21&type=section&id=Macroeconomic%20Considerations) This section discusses potential impacts of broader economic and geopolitical factors on the company's business - Unfavorable macroeconomic events, such as changes in inflation, interest rates, international trade policies, and geopolitical tensions (e.g., Russia-Ukraine war, Middle East conflict), may negatively affect business growth and results of operations[97](index=97&type=chunk) - The impact of these uncertainties on financial estimates and clinical trial plans, including enrollment and timelines, is uncertain and cannot be fully predicted[78](index=78&type=chunk)[97](index=97&type=chunk) [Our Key Agreements](index=21&type=section&id=Our%20Key%20Agreements) This section references the company's significant contractual agreements, including licensing and manufacturing deals - Key agreements include the License Agreement with HanAll for IMVT-1402 and batoclimab, and the Product Service Agreement with Samsung Biologics for batoclimab manufacturing[99](index=99&type=chunk)[100](index=100&type=chunk) - Related party transactions are detailed in Note 5 of the financial statements[101](index=101&type=chunk) [Financial Operations Overview](index=22&type=section&id=Financial%20Operations%20Overview) This section provides a high-level summary of the company's financial performance and operational drivers [Revenue](index=22&type=section&id=Revenue) This section discusses the company's revenue recognition policies and current revenue status - The company has not generated any revenue since inception and does not expect to until regulatory approval and commercialization of its product candidates[102](index=102&type=chunk) - Profitability is entirely dependent on the successful development and commercialization of IMVT-1402, batoclimab, or future product candidates[102](index=102&type=chunk) [Research and Development Expenses](index=22&type=section&id=Research%20and%20Development%20Expenses) This section details the components and trends of the company's research and development expenditures - R&D expenses primarily consist of therapeutic area-specific costs (direct third-party costs, contract manufacturing) and unallocated costs (personnel-related, stock-based compensation, services agreements, other expenses)[103](index=103&type=chunk)[104](index=104&type=chunk)[106](index=106&type=chunk) - The company expects R&D expenses to continue increasing due to ongoing IMVT-1402 trials (GD, D2T RA, MG, CIDP, SjD, CLE), batoclimab trials (TED, GD), manufacturing, and regulatory preparations[105](index=105&type=chunk) - The duration, costs, and timing of clinical trials are subject to various factors, including the number of trials, per-patient costs, patient enrollment, regulatory requirements, and manufacturing costs[107](index=107&type=chunk)[112](index=112&type=chunk) [General and Administrative Expenses](index=23&type=section&id=General%20and%20Administrative%20Expenses) This section outlines the components and trends of the company's general and administrative expenditures - G&A expenses include employee salaries, benefits, stock-based compensation for G&A personnel, legal and accounting fees, consulting services, and costs allocated under Services Agreements[109](index=109&type=chunk) - G&A expenses are expected to increase to support R&D activities, patent-related costs, and potentially market research and commercial team building if product candidates receive regulatory approval[110](index=110&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section analyzes the company's financial results for the reporting period, focusing on key income statement items Condensed Consolidated Statements of Operations (in thousands) | Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | | :-------------------------------- | :------------------------------- | :------------------------------- | :------- | | Research and development | $101,200 | $75,473 | $25,727 | | General and administrative | $26,024 | $18,808 | $7,216 | | **Total operating expenses** | **$127,224** | **$94,281** | **$32,943** | | Interest income, net | $(6,337) | $(7,180) | $843 | | Other income, net | $(1,187) | $(28) | $(1,159) | | Loss before provision for income taxes | $(119,700) | $(87,073) | $(32,627) | | Provision for income taxes | $913 | $77 | $836 | | **Net loss** | **$(120,613)** | **$(87,150)** | **$(33,463)** | - Net loss increased by **$33.5 million** (**38.4%**) from **$87.2 million** in Q2 2024 to **$120.6 million** in Q2 2025[15](index=15&type=chunk)[111](index=111&type=chunk) - Total operating expenses increased by **$32.9 million** (**34.9%**) to **$127.2 million** in Q2 2025, primarily due to higher R&D and G&A expenses[15](index=15&type=chunk)[111](index=111&type=chunk) [Research and Development Expenses](index=24&type=section&id=Research%20and%20Development%20Expenses%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section details the company's investments in research and development activities for its product candidates Research and Development Expenses (in thousands) | Category | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | | :------------------------------------------ | :------------------------------- | :------------------------------- | :------- | | Therapeutic area-specific costs | $56,012 | $40,793 | $15,219 | | Unallocated costs (Personnel-related) | $34,503 | $24,520 | $9,983 | | Unallocated costs (Other) | $10,685 | $10,160 | $525 | | **Total research and development expenses** | **$101,200** | **$75,473** | **$25,727** | - R&D expenses increased by **$25.7 million** (**34.1%**) year-over-year, primarily due to new IMVT-1402 registrational trials in rheumatology (**$8.2 million**) and dermatology (**$5.1 million**) diseases[114](index=114&type=chunk)[115](index=115&type=chunk) - Unallocated R&D costs increased by **$10.5 million**, mainly due to a **$10.0 million** rise in personnel-related expenses driven by higher headcount for increased clinical trials[116](index=116&type=chunk) [General and Administrative Expenses](index=24&type=section&id=General%20and%20Administrative%20Expenses%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section outlines the company's administrative and overhead costs supporting its operations General and Administrative Expenses (in thousands) | Period | General and Administrative Expenses | | :------------------------------- | :---------------------------------- | | Three Months Ended June 30, 2025 | $26,024 | | Three Months Ended June 30, 2024 | $18,808 | | **Change** | **$7,216** | - The **$7.2 million** increase in G&A expenses was primarily due to higher personnel-related expenses, including a one-time stock-based compensation charge related to the former CEO's retirement[117](index=117&type=chunk) [Interest Income, net](index=24&type=section&id=Interest%20Income%2C%20net%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section reports the company's net interest income or expense from its cash and investments Interest Income, net (in thousands) | Period | Interest Income, net | | :------------------------------- | :------------------- | | Three Months Ended June 30, 2025 | $(6,337) | | Three Months Ended June 30, 2024 | $(7,180) | | **Change** | **$843** | - Interest income decreased by **$0.8 million**, primarily reflecting lower average interest rates, partially offset by higher average money market fund balances[118](index=118&type=chunk) [Liquidity and Capital Resources](index=25&type=section&id=Liquidity%20and%20Capital%20Resources) This section assesses the company's cash position, funding sources, and future capital requirements [Sources of Liquidity](index=25&type=section&id=Sources%20of%20Liquidity) This section describes how the company obtains and manages its cash and capital resources Cash and Cash Equivalents (in millions) | Date | Amount | | :--------------- | :----- | | June 30, 2025 | $598.9 | | March 31, 2025 | $714.0 | - The company has incurred significant operating losses and negative cash flows, with net losses of **$120.6 million** and **$87.2 million** for the three months ended June 30, 2025 and 2024, respectively[120](index=120&type=chunk) - Future cash needs are expected to be financed through equity offerings, debt financings, and potential collaboration or license agreements, as the company has no committed external source of funds[121](index=121&type=chunk)[122](index=122&type=chunk) - The company has an automatic shelf registration statement for up to **$150.0 million** in ATM Shares but has not yet issued or sold any[123](index=123&type=chunk) [Cash Flows](index=25&type=section&id=Cash%20Flows) This section analyzes the company's cash inflows and outflows from operating, investing, and financing activities Summary of Cash Flows (in thousands) | Activity | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | | Net cash used in operating activities | $(117,411) | $(76,199) | | Net cash used in investing activities | $0 | $(182) | | Net cash provided by financing activities | $2,918 | $686 | - Net cash used in operating activities increased to **$117.4 million** in Q2 2025 from **$76.2 million** in Q2 2024, primarily due to a higher net loss and changes in operating assets and liabilities[126](index=126&type=chunk)[127](index=127&type=chunk) - Cash provided by financing activities increased to **$2.9 million** in Q2 2025 from **$0.7 million** in Q2 2024, driven by proceeds from stock options exercised[129](index=129&type=chunk) [Material Cash Requirements](index=26&type=section&id=Material%20Cash%20Requirements) This section identifies significant future cash obligations and commitments Samsung Biologics Minimum Purchase Obligation (as of June 30, 2025) | Fiscal Year Ending March 31 | Amount (in millions) | | :---------------------------- | :------------------- | | Remainder of FY2026 | $5.0 | | FY2028 | $10.1 | | FY2029 | $14.0 | | FY2030 | $14.0 | | **Total Remaining Obligation** | **$43.1** | - Potential future milestone payments under the HanAll Agreement could reach an aggregate maximum of **$420.0 million**, contingent upon regulatory and sales milestones[133](index=133&type=chunk) - Future capital requirements are expected to increase significantly to fund clinical development, launch new trials, increase manufacturing, achieve milestones, expand intellectual property, hire personnel, and build commercial infrastructure[136](index=136&type=chunk)[137](index=137&type=chunk) [Outlook](index=27&type=section&id=Outlook) This section provides the company's forward-looking perspective on its financial position and operations - Existing cash and cash equivalents of **$598.9 million** as of June 30, 2025, are expected to fund operating expenses and capital expenditures for announced indications through the GD readout expected in **2027**[134](index=134&type=chunk) - Current funds are insufficient to complete all necessary development and commercially launch IMVT-1402 or batoclimab, and the company anticipates incurring net losses for the foreseeable future[136](index=136&type=chunk) [Critical Accounting Estimates](index=28&type=section&id=Critical%20Accounting%20Estimates) This section explains the significant accounting estimates and judgments used in preparing the financial statements - The preparation of financial statements requires subjective estimates and judgments about uncertain matters that materially impact financial condition and results of operations[138](index=138&type=chunk) - No material changes to critical accounting estimates were made during the three months ended June 30, 2025, compared to the prior Annual Report[139](index=139&type=chunk) [Recent Accounting Pronouncements](index=28&type=section&id=Recent%20Accounting%20Pronouncements) This section discusses the impact of newly issued accounting standards on the company's financial reporting - ASU 2023-09 (Income Taxes) requires disaggregated information on effective rate reconciliation and income taxes paid by jurisdiction, effective for fiscal years beginning after December 15, 2024[44](index=44&type=chunk) - ASU 2024-03 (Expense Disaggregation) requires disclosures about specific types of expenses on the income statement, effective for fiscal years beginning after December 15, 2026[45](index=45&type=chunk) - Other recent guidance is not expected to have a material impact on the financial statements[46](index=46&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=29&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section details the company's exposure to market risks, primarily interest rate fluctuations, and their potential financial impact - Primary market risk is interest income volatility, but a hypothetical **10%** change in interest rates would not materially affect liquidity due to investments in high-quality, short-term U.S. government securities[142](index=142&type=chunk) - The company is not currently exposed to significant foreign currency exchange rate risk, as most operations and expenses are U.S. dollar-denominated[143](index=143&type=chunk) - Inflation has not had a material effect on the company's business, financial condition, or results of operations as of June 30, 2025[144](index=144&type=chunk) [Item 4. Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures) This section assesses the effectiveness of the company's disclosure controls and internal control over financial reporting - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2025, at the reasonable assurance level[147](index=147&type=chunk) - No material changes in internal control over financial reporting occurred during the fiscal quarter ended June 30, 2025[148](index=148&type=chunk) - Control systems provide only reasonable, not absolute, assurance that objectives are met, acknowledging inherent limitations and resource constraints[149](index=149&type=chunk) PART II. OTHER INFORMATION This section presents additional disclosures not covered in the financial statements, including legal, risk, and equity matters [Item 1. Legal Proceedings](index=31&type=section&id=Item%201.%20Legal%20Proceedings) This section outlines any material legal or regulatory proceedings affecting the company's business or financial condition - The company does not currently expect any legal or regulatory proceedings to have a material adverse effect on its business, operating results, or financial condition[150](index=150&type=chunk) - Further details on legal proceedings are provided in Note 10 – Commitments and Contingencies[151](index=151&type=chunk) [Item 1A. Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) This section identifies and discusses significant risks that could materially impact the company's business, operations, and financial results - The company's business involves a high degree of risk, and risk factors have not materially changed from the Annual Report, except as noted[152](index=152&type=chunk) - Reliance on the HanAll Agreement for core intellectual property rights to IMVT-1402 and batoclimab is a critical risk; termination or loss of rights would adversely affect development and commercialization[153](index=153&type=chunk)[156](index=156&type=chunk)[157](index=157&type=chunk) - Potential disputes with HanAll regarding batoclimab development or commercialization plans could be expensive, time-consuming, and materially impact the business[155](index=155&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section reports on any unregistered sales of equity securities and the use of proceeds during the period - None[158](index=158&type=chunk) [Item 3. Defaults Upon Senior Securities](index=32&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section discloses any defaults on senior securities during the reporting period - None[159](index=159&type=chunk) [Item 4. Mine Safety Disclosures](index=32&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section provides mine safety disclosures, if applicable to the company's operations - Not applicable[160](index=160&type=chunk) [Item 5. Other Information](index=32&type=section&id=Item%205.%20Other%20Information) This section includes any other material information not specifically covered in other items - No directors or Section 16 reporting officers adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter ended June 30, 2025[161](index=161&type=chunk) [Item 6. Exhibits](index=33&type=section&id=Item%206.%20Exhibits) This section lists all documents filed as exhibits to the report, including agreements and certifications - The exhibits include the Share Exchange Agreement, Amended and Restated Certificate of Incorporation and Bylaws, employment and separation agreements for key personnel, and equity incentive plan documents[162](index=162&type=chunk) - Certifications from the Chief Executive Officer and Chief Financial Officer pursuant to the Securities Exchange Act and Sarbanes-Oxley Act are included[162](index=162&type=chunk) [SIGNATURES](index=34&type=section&id=SIGNATURES) This section contains the official signatures certifying the accuracy and submission of the report - The report was signed by Eric Venker, M.D., Pharm.D., Chief Executive Officer, and Tiago Girao, Chief Financial Officer, on August 11, 2025[168](index=168&type=chunk)

Financial Performance - As of June 30, 2025, Immunovant's cash and cash equivalents totaled approximately $598.9 million, providing runway for announced indications through GD readout expected in 2027[6] - Research and development (R&D) expenses for the three months ended June 30, 2025, were $101.2 million, an increase of 34% from $75.5 million for the same period in 2024[7] - General and administrative (G&A) expenses for the three months ended June 30, 2025, were $26.0 million, up from $18.8 million in the prior year, reflecting a 38% increase[10] - The net loss for the three months ended June 30, 2025, was $120.6 million ($0.71 per common share), compared to a net loss of $87.2 million ($0.60 per common share) for the same period in 2024, representing a 38% increase in net loss[11] - Non-GAAP net loss for the three months ended June 30, 2025, was $102.1 million, compared to $73.8 million for the same period in 2024, indicating a 38% increase[11] - The total operating expenses for the three months ended June 30, 2025, were $127.2 million, compared to $94.3 million for the same period in 2024, reflecting a 35% increase[18] Clinical Development - Immunovant initiated a second potentially registrational trial for IMVT-1402 in Graves' disease (GD) and Sjögren's disease (SjD) in June 2025, with all clinical development timelines remaining on track[3] - Results from the open-label portion of the potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) are expected in calendar year 2026[5] - Top-line results from the proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus (CLE) are also anticipated in calendar year 2026[5] Share Information - As of June 30, 2025, there were 171,069,176 shares of common stock issued and outstanding[12]

Core Insights - Immunovant, Inc. reported corporate updates and financial results for the quarter ended June 30, 2025, focusing on its clinical-stage immunology developments and financial performance [1][4]. Recent Highlights and Upcoming Milestones - In June 2025, Immunovant initiated two potentially registrational trials for IMVT-1402, one for Graves' disease (GD) and another for Sjögren's disease (SjD) [1][10]. - The company is on track with clinical development timelines for IMVT-1402 across six indications, including GD, difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), SjD, and a proof-of-concept trial in cutaneous lupus erythematosus (CLE) [1][10]. - Remission data from the batoclimab proof-of-concept study in GD is expected to be reported at the American Thyroid Association Annual Meeting in September 2025 [2][10]. - Results from the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA and top-line results from the proof-of-concept trial in CLE are anticipated in 2026 [3]. Financial Highlights - As of June 30, 2025, Immunovant's cash and cash equivalents totaled approximately $598.9 million, providing a runway for announced indications through the GD readout expected in 2027 [4][10]. - Research and development (R&D) expenses for the three months ended June 30, 2025, were $101.2 million, an increase from $75.5 million for the same period in 2024, primarily due to clinical trial activities for IMVT-1402 [5][6]. - General and administrative (G&A) expenses rose to $26.0 million for the three months ended June 30, 2025, compared to $18.8 million for the same period in 2024, mainly due to higher personnel-related expenses [6][7]. - The net loss for the three months ended June 30, 2025, was $120.6 million ($0.71 per common share), compared to a net loss of $87.2 million ($0.60 per common share) for the same period in 2024 [8][15].

Core Viewpoint - Immunovant, Inc. (IMVT) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - For the fiscal year ending March 2026, Immunovant is expected to earn -$2.90 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, where Zacks Rank 1 stocks have generated an average annual return of +25% since 1988 [7]. - The upgrade of Immunovant to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Immunovant, Inc. (IMVT) shows significant upside potential with a mean price target of $41.57, indicating a 137.7% increase from the current price of $17.49 [1] Price Targets and Analyst Consensus - The average of 14 short-term price targets ranges from a low of $17.00 to a high of $61.00, with a standard deviation of $15.37, suggesting variability in analyst estimates [2] - The lowest estimate indicates a potential decline of 2.8%, while the highest suggests a 248.8% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about IMVT's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, two estimates have been revised higher, leading to a 3.4% increase in the Zacks Consensus Estimate [12] - IMVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][7] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [10]

Summary of Roivant Sciences (ROIV) Conference Call Company Overview - Roivant Sciences is a clinical stage biopharma company focused on developing valuable medicines with a portfolio of late-stage programs [4][5] - The company has approximately $5 billion in cash, primarily from a previous transaction involving an anti T1 antibody [6] Key Programs and Pipeline - **Anti FcRn Franchise**: Developed through subsidiary Immunovant, focusing on indications like Graves' disease and myasthenia gravis (MG) [5][59] - **JAK1/TYK2 Inhibitor**: Targeting dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis [5] - **PHLD Program**: Known as Mosley Siguat, with significant data expected in the near future [5] - Upcoming phase three readout for dermatomyositis expected in the second half of the year, which could lead to a commercial launch [7][24] Market Opportunities - The dermatomyositis market is estimated to have around 40,000 to 70,000 patients, with the potential for Roivant to be the first oral novel medication in this space [27][28] - The company anticipates a significant commercial opportunity, with pricing expected to be competitive with existing therapies like IVIG [52][51] Business Development (BD) Strategy - The current biotech market presents opportunities for Roivant as valuations decrease and expectations shift [11][12] - The company is exploring indication expansions organically, particularly in the FcRn and JAK1/TYK2 areas [13][14] - Roivant is open to various therapeutic areas, including immunology, respiratory, and rare diseases, while being cautious about competitive dynamics in oncology and gene therapy [20] Regulatory and Clinical Considerations - The company is focused on achieving orphan drug designation for its dermatomyositis treatment, which provides benefits in user fees and FDA engagement [41][42] - The primary endpoint for the phase three trial is a statistically significant improvement in the Total Improvement Score (TIS) [30][40] - Placebo effects are a concern, but the company is implementing strategies to mitigate these risks, including a mandatory steroid taper in the trial protocol [34][39] Immunovant and Future Prospects - Immunovant's lead drug, IMG1402, is in pivotal trials for multiple indications, with promising data supporting deeper IgG suppression leading to better clinical outcomes [59][60] - The company aims to redefine success metrics in MG, moving towards deeper clinical responses rather than just baseline improvements [63][65] - Roivant holds a 58% stake in Immunovant and is optimistic about the potential for multiple blockbuster indications [72][74] Legal Matters - Roivant is involved in patent litigation against Pfizer and Moderna regarding their COVID-19 vaccines, with expectations for a trial in the near future [76][77] Conclusion - Roivant Sciences is positioned for significant growth with a robust pipeline and strategic focus on valuable therapeutic areas, while navigating challenges in the current biotech landscape and legal environment [4][11][76]

Core Viewpoint - Immunovant, Inc. (IMVT) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system focuses on changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Company Performance and Outlook - The recent upgrade for Immunovant suggests an improvement in its underlying business, which should encourage investors to drive the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for Immunovant has increased by 1.1%, although the company is expected to report a loss of -$3.03 per share for the fiscal year ending March 2026, reflecting an 11% year-over-year decline [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating, indicating superior earnings estimate revisions [9][10]. - The upgrade of Immunovant to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Insights - Immunovant, Inc. reported a narrower net loss of 64 cents per share for Q4 fiscal 2025, compared to a loss of 72 cents estimated by Zacks Consensus, but wider than the previous year's loss of 52 cents per share [1] - The stock price increased by 5.6% following the earnings report, despite a year-to-date decline of 39.9% compared to the industry’s 3.5% decline [1] Financial Performance - Research and development expenses rose to $93.7 million, a 42% increase from the previous year, driven by clinical study activities for IMVT-1402 and related costs [2] - General and administrative expenses increased to $20.2 million, up 36% year over year, primarily due to higher personnel-related expenses and professional fees [3] - As of March 31, 2025, the company had a cash balance of $714 million, significantly up from $374.7 million as of December 31, 2024, providing a cash runway expected to fund operations through 2027 [3] Fiscal Year Results - For fiscal 2025, Immunovant reported a loss of $2.73 per share, matching the Zacks Consensus Estimate, compared to a loss of $1.88 per share in the previous fiscal year [5] Pipeline Developments - IMVT-1402 is designated as the lead asset, with plans to initiate clinical studies in 10 indications by March 31, 2026, leveraging existing data from batoclimab studies for financial efficiencies [6] - The company is currently developing IMVT-1402 for six indications, including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren's disease, and cutaneous lupus erythematosus [7] - Registrational studies for IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy are currently enrolling patients, with additional studies for Graves' disease expected to begin in summer 2025 [8][9] Additional Candidate Evaluation - Immunovant is also evaluating batoclimab in mid-late-stage studies for Graves' disease and thyroid eye disease, with new proof-of-concept data expected in summer 2025 [10] - Top-line data from the late-stage thyroid eye disease study of batoclimab is anticipated in the second half of 2025, which will inform regulatory filing decisions [11]